Improving treatment outcomes for MDR-TB — Novel host-directed therapies and personalised medicine of the future

Improving treatment outcomes for MDR-TB — Novel host-directed therapies and personalised medicine of the future

Multidrug-resistant TB (MDR-TB) is a major threat to global health security. In 2017, only 50% of patients with MDR-TB who received WHO-recommended treatment were cured. Most MDR-TB patients who recover continue to suffer from functional disability due to long-term lung damage. Whilst new MDR-TB tre...

Full description

Bibliographic Details
Main Authors:	Martin Rao, Giuseppe Ippolito, Sayoki Mfinanga, Francine Ntoumi, Dorothy Yeboah-Manu, Cris Vilaplana, Alimuddin Zumla, Markus Maeurer
Format:	Article
Language:	English
Published:	Elsevier 2019-03-01
Series:	International Journal of Infectious Diseases
Online Access:	http://www.sciencedirect.com/science/article/pii/S1201971219300505

Similar Items

Latent TB Infection (LTBI) – Mycobacterium tuberculosis pathogenesis and the dynamics of the granuloma battleground
by: Martin Rao, et al.
Published: (2019-03-01)

Blue Skies research is essential for ending the Tuberculosis pandemic and advancing a personalized medicine approach for holistic management of Respiratory Tract infections.
by: Francine Ntoumi, et al.
Published: (2022-11-01)

Taking forward the Stop TB Partnership and World Health Organization Joint Theme for World TB Day March 24th 2018 — “Wanted: Leaders for a TB-Free World. You can make history. End TB”
by: Simon Tiberi, et al.
Published: (2018-03-01)

Learning from epidemiological, clinical, and immunological studies on Mycobacterium africanum for improving current understanding of host–pathogen interactions, and for the development and evaluation of diagnostics, host-directed therapies, and vaccines for tuberculosis
by: Alimuddin Zumla, et al.
Published: (2017-03-01)

Host-directed therapies for multidrug resistant tuberculosis
by: Alimuddin Zumla, et al.
Published: (2016-01-01)

Immunometabolism and Pulmonary Infections: Implications for Protective Immune Responses and Host-Directed Therapies
by: Martin Rao, et al.
Published: (2019-05-01)

Tuberculin skin test – Outdated or still useful for Latent TB infection screening?
by: Gina Gualano, et al.
Published: (2019-03-01)

‘ZS-MDR-TB’ versus ‘ZR-MDR-TB’: improving treatment of MDR-TB by identifying pyrazinamide susceptibility
by: Ying Zhang, et al.
Published: (2012-07-01)

World TB Day 2022: Revamping and Reshaping Global TB Control Programs by Advancing Lessons learnt from the COVID-19 pandemic
by: Eskild Petersen, et al.
Published: (2022-11-01)

The WHO Global Tuberculosis 2021 Report – not so good news and turning the tide back to End TB
by: Jeremiah Chakaya, et al.
Published: (2022-11-01)

Host-directed therapies for tuberculous pericarditis
by: Alimuddin Zumla, et al.
Published: (2015-03-01)

Relevance of genomic diversity of Mycobacterium tuberculosis complex in Africa
by: Stephen Osei-Wusu, et al.
Published: (2022-11-01)

Middle East Respiratory Syndrome - need for increased vigilance and watchful surveillance for MERS-CoV in sub-Saharan Africa
by: Alimuddin Zumla, et al.
Published: (2015-08-01)

Evaluation of the efficacy of valproic acid and suberoylanilide hydroxamic acid (vorinostat) in enhancing the effects of first-line tuberculosis drugs against intracellular Mycobacterium tuberculosis
by: Martin Rao, et al.
Published: (2018-04-01)

Taking forward a ‘One Health’ approach for turning the tide against the Middle East respiratory syndrome coronavirus and other zoonotic pathogens with epidemic potential
by: Alimuddin Zumla, et al.
Published: (2016-06-01)

MDR-TB TREATMENT UPDATE
by: Sean Wasserman
Published: (2023-05-01)

MDR TB Transmission, Singapore
by: Cynthia B.E. Chee, et al.
Published: (2013-07-01)

Tuberculosis, HIV/AIDS and Malaria Health Services in sub-Saharan Africa – A Situation Analysis of the Disruptions and Impact of the COVID-19 Pandemic
by: Pascalina Chanda-Kapata, et al.
Published: (2022-11-01)

Impact of infectious disease epidemics on tuberculosis diagnostic, management, and prevention services: experiences and lessons from the 2014–2015 Ebola virus disease outbreak in West Africa
by: Rashid Ansumana, et al.
Published: (2017-03-01)

Global Tuberculosis Report 2020 – Reflections on the Global TB burden, treatment and prevention efforts
by: Jeremiah Chakaya, et al.
Published: (2021-12-01)

Mycobacterium tuberculosis proteins involved in cell wall lipid biosynthesis improve BCG vaccine efficacy in a murine TB model
by: Martin Rao, et al.
Published: (2017-03-01)

RELATIONSHIP BETWEEN DETECTION OF TB AND TREATMENT OF MDR/XDR TB
by: V. Guseva, et al.
Published: (2023-08-01)

Community-based MDR-TB care project improves treatment initiation in patients diagnosed with MDR-TB in Myanmar.
by: Pyae Phyo Wai, et al.
Published: (2018-01-01)

Anti-PD-1/PD-L1 therapy for infectious diseases: learning from the cancer paradigm
by: Martin Rao, et al.
Published: (2017-03-01)

Management of MDR-TB at the University Hospital of Kinshasa
by: J.M.N. Kayembe, et al.
Published: (2014-04-01)

Commemorating World TB Day 2020: “IT’S TIME” — It’s time to End the Global TB Epidemic
by: Simon Tiberi, et al.
Published: (2020-03-01)

The incidence of TB and MDR-TB in pediatrics and therapeutic options: a systematic review
by: Sheetal Harichander, et al.
Published: (2022-08-01)

A compartmental model on the effect of quarantine on MDR-TB
by: Yeketi, Ayinla Ally, et al.
Published: (2019)

Why has MDR-TB prevalence increased in Iran?
by: Mohsen Heidary, et al.
Published: (2016-12-01)

Predictors of Multidrug-Resistant Tuberculosis (MDR-TB) in Sudan
by: Monadil H. Ali, et al.
Published: (2019-07-01)

Molecular characterization of multidrug-resistant Mycobacterium tuberculosis (MDR-TB) isolates identifies local transmission of infection in Kuwait, a country with a low incidence of TB and MDR-TB
by: Noura M. Al-Mutairi, et al.
Published: (2019-12-01)

Analysis of multi drug resistant tuberculosis (MDR-TB) financial protection policy: MDR-TB health insurance schemes, in Chhattisgarh state, India
by: Debashish Kundu, et al.
Published: (2018-01-01)

Accelerating development of new shorter TB treatment regimens in anticipation of a resurgence of multi-drug resistant TB due to the COVID-19 pandemic
by: Simon Tiberi, et al.
Published: (2021-12-01)

Correction: The incidence of TB and MDR-TB in pediatrics and therapeutic options: a systematic review
by: Sheetal Harichander, et al.
Published: (2022-10-01)

Isolation, biochemical and molecular identification of Nocardia species among TB suspects in northeastern, Tanzania; a forgotten or neglected threat?
by: Abubakar S. Hoza, et al.
Published: (2017-06-01)

Correction to: Molecular characterization of multidrug-resistant Mycobacterium tuberculosis (MDR-TB) isolates identifies local transmission of infection in Kuwait, a country with a low incidence of TB and MDR-TB
by: Noura M. Al-Mutairi, et al.
Published: (2020-04-01)

Achieving sustainable development goals for HIV/AIDS in the Republic of the Congo — Progress, obstacles and challenges in HIV/AIDS health services
by: Laure Stella Ghoma Linguissi, et al.
Published: (2018-12-01)

Disadvantage and the experience of treatment for multidrug-resistant tuberculosis (MDR-TB)
by: Holly A. Taylor, et al.
Published: (2022-12-01)

Six-Month Response to Delamanid Treatment in MDR TB Patients
by: Cathy Hewison, et al.
Published: (2017-10-01)

STUDI DESKRIPTIF PASIEN TB MDR DI SULAWESI SELATAN
by: Ikes Dwiastuti, et al.
Published: (2020-02-01)